Emerging in the field of excess body fat treatment, retatrutide presents a different approach. Different from many available medications, retatrutide operates as a twin agonist, simultaneously affecting both GLP-like peptide-1 (GLP-1) and glucose-responsive insulinotropic substance (GIP) receptors. The dual activation fosters multiple advantageous